Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2003-09-04 Capital/Financing Update
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appointed to commercialise new gene invention 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a company announcement addressed to the Australian Stock Exchange, dated 5 September 2003. It announces a new commercial agreement between Genetic Technologies Limited and the University of Sydney regarding a genetic invention. The content focuses on the business development and commercialisation of a new genetic test, including strategic alliances and potential market impact. There are no financial statements, quarterly or annual results, nor is this a regulatory certification or voting result. The document is an update on a capital or business development activity related to commercialisation rights, which fits best under Capital/Financing Update (CAP). The document length is short (3044 characters) and it is not a report publication announcement or a regulatory filing. Therefore, the classification is CAP with high confidence.
2003-09-04 English
Change of Director's Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and references Rule 3.19A.2, which pertains to the 'Change of Director's Interest Notice'. It details changes in securities holdings by a director, including the number of shares disposed and held before and after the change, as well as the nature of the transaction (off-market trade). This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report or a certification. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content fully support this classification with high confidence.
2003-09-04 English
Appendix 3B - New Issue 10 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and contains detailed information about the issuance of new securities, including ordinary shares and unlisted options, their issue prices, exercise prices, expiry dates, and the purpose of the issue. It references ASX (Australian Securities Exchange) rules and provides specifics on the number and class of securities issued or to be issued. This type of document is a formal announcement related to capital raising activities and changes in the company's capital structure. It is not a full financial report, earnings release, or management discussion. The content aligns with a Capital/Financing Update, which covers company fundraising and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2003-09-03 English
Professor Quinn joins Scientific Advisory Committee 2 pages ?Kb
Board/Management Information Classification · 95% confidence The document is a short announcement dated 2 September 2003, addressed to the Australian Stock Exchange Company Announcements Office. It announces the appointment of Professor Michael Quinn to the Scientific Advisory Committee of Genetic Technologies Limited. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no legal proceedings, no capital changes, and no report attachments. The content is about a management/board-related appointment, specifically a scientific advisory committee member, which falls under management or board information. Given the nature of the announcement about a senior advisory committee member joining, the most appropriate classification is Board/Management Information (MANG). The document length is short (2326 characters), consistent with an announcement rather than a full report. Confidence is high due to clear content and context.
2003-09-01 English
Professor Easteal joins GTG Scientific Advisory Committee 2 pages ?Kb
Board/Management Information Classification · 95% confidence The document is a company announcement dated 1 September 2003, addressed to the Australian Stock Exchange Limited. It announces the appointment of Professor Simon Easteal to the Scientific Advisory Committee of Genetic Technologies Limited. The content focuses on the advisory role and expertise of the new committee member, with no financial data, report references, or regulatory filings mentioned. The document length is short (2958 characters) and is clearly an announcement of a management/board-related change, specifically the addition of a scientific advisory committee member. This fits best under Board/Management Information (MANG).
2003-08-31 English
Prof Masters joins Scientific Advisory Committee 2 pages ?Kb
Board/Management Information Classification · 95% confidence The document is a company announcement dated 29 August 2003, addressed to the Australian Stock Exchange. It announces the appointment of Professor Colin L. Masters to the Scientific Advisory Committee of Genetic Technologies Limited. The content focuses on management/board level information about a new advisory committee member and does not contain financial data, regulatory filings, or report publications. It is not a full report, earnings release, or any financial statement. Therefore, it fits best under Board/Management Information (MANG) as it relates to changes or updates in senior management or advisory roles.
2003-08-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.